Stockscreener 앱 받기
137.77
1.21%
1.6575
전일 마감가:
$136.11
열려 있는:
$136.32
하루 거래량:
93,333
Relative Volume:
0.10
시가총액:
$13.67B
수익:
$2.41B
순이익/손실:
$305.80M
주가수익비율:
46.70
EPS:
2.95
순현금흐름:
$492.20M
1주 성능:
-0.85%
1개월 성능:
+7.59%
6개월 성능:
+21.79%
1년 성능:
+12.42%
1일 변동 폭
$135.66
$138.75
1주일 범위
$135.61
$142.91
52주 변동 폭
$84.23
$154.61
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
NBIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
137.81 | 14.08B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
151.98 | 67.75B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.23 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.8703 | 43.70B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.62 | 21.51B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
384.44 | 18.31B | 2.99B | 1.21B | 1.13B | 25.06 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
Neurocrine Biosciences Shares Dip 4.09% on Strong Volume Surge to 478th Rank Amid Q2 Earnings Boost - AInvest
Neurocrine Biosciences' Strategic Position in the CNS Therapeutics Market - AInvest
Transcript : Neurocrine Biosciences, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-03-2025 01 - MarketScreener
Does Neurocrine Biosciences Inc. qualify in momentum factor screeningJuly 2025 Big Picture & Stepwise Entry and Exit Trade Signals - Newser
Endometriosis Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine - Barchart.com
What to expect from Neurocrine Biosciences Inc. in the next 30 daysJuly 2025 Final Week & Accurate Buy Signal Alerts - Newser
Is a relief rally coming for Neurocrine Biosciences Inc. holdersMarket Performance Recap & Breakout Confirmation Alerts - Newser
Neurocrine Biosciences Inc. stock retracement – recovery analysisJuly 2025 Review & Capital Protection Trading Alerts - Newser
Will Neurocrine Biosciences Inc. stock recover after recent dropBull Run & Weekly Top Gainers Trade List - Newser
Risk vs reward if holding onto Neurocrine Biosciences Inc.July 2025 Volume & Trade Opportunity Analysis Reports - Newser
Custom watchlist performance reports with Neurocrine Biosciences Inc.Portfolio Profit Report & Real-Time Buy Zone Alerts - Newser
What’s next for Neurocrine Biosciences Inc. stock priceEarnings Performance Report & Stepwise Entry and Exit Trade Signals - Newser
Long term hold vs stop loss in Neurocrine Biosciences Inc.2025 Volatility Report & Real-Time Chart Pattern Alerts - Newser
Is Neurocrine Biosciences Inc. a cyclical or defensive stockWeekly Trade Summary & Breakout Confirmation Trade Signals - khodrobank.com
Will Neurocrine Biosciences Inc. stock hit new highs in YEARQuarterly Market Review & Stock Market Timing Techniques - khodrobank.com
Is Neurocrine Biosciences Inc. showing signs of accumulation2025 Top Gainers & Fast Gaining Stock Reports - Newser
Is Neurocrine Biosciences Inc. being accumulated by smart moneyJuly 2025 Levels & Fast Entry and Exit Trade Plans - khodrobank.com
Technical Bounce Expected in Neurocrine Biosciences Inc. Next Week getLinesFromResByArray error: size == 0 - thegnnews.com
Tick level data insight on Neurocrine Biosciences Inc. volatilityMarket Growth Review & Free Fast Gain Swing Trade Alerts - Newser
Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access - Yahoo Finance
Neurocrine Biosciences Inc. recovery potential after sell offLayoff News & Real-Time Volume Analysis Alerts - Newser
Can Neurocrine Biosciences Inc. hit a new high this monthTrade Ideas & AI Optimized Trading Strategy Guides - Newser
Does Neurocrine Biosciences Inc. fit your quant trading modelInsider Buying & Technical Confirmation Trade Alerts - Newser
Is Neurocrine Biosciences Inc. forming a reversal patternVolume Spike & Reliable Price Action Trade Plans - Newser
Understanding Neurocrine Biosciences Inc.’s price movement2025 Technical Patterns & High Yield Stock Recommendations - Newser
Will Neurocrine Biosciences Inc. stock go up soonMarket Performance Recap & AI Driven Stock Price Forecasts - Newser
Real time social sentiment graph for Neurocrine Biosciences Inc.Jobs Report & Weekly Breakout Opportunity Watchlist - Newser
Tools to monitor Neurocrine Biosciences Inc. recovery probabilityTrade Ideas & AI Enhanced Trading Signals - Newser
Historical volatility pattern of Neurocrine Biosciences Inc. visualizedMarket Performance Recap & Low Drawdown Investment Ideas - Newser
Will Neurocrine Biosciences Inc. outperform small cap indexes2025 Historical Comparison & Real-Time Volume Trigger Notifications - sundaytimes.kr
How Neurocrine Biosciences Inc. stock performs during market volatilityMarket Growth Summary & Weekly Setup with High ROI Potential - Newser
How to integrate Neurocrine Biosciences Inc. into portfolio analysis toolsEarnings Miss & Technical Entry and Exit Alerts - Newser
Ranking Neurocrine Biosciences Inc. among high performing stocks via tools2025 Macro Impact & Verified Momentum Stock Ideas - Newser
What Fibonacci levels say about Neurocrine Biosciences Inc. reboundProduct Launch & Verified High Yield Trade Plans - Newser
Will Neurocrine Biosciences Inc. price bounce be sustainableJuly 2025 Setups & Consistent Growth Equity Picks - Newser
Real time scanner hits for Neurocrine Biosciences Inc. explainedStop Loss & Weekly High Return Opportunities - Newser
Relative strength of Neurocrine Biosciences Inc. in sector analysisJuly 2025 Earnings & Real-Time Volume Analysis - Newser
Is it too late to sell Neurocrine Biosciences Inc.Quarterly Performance Summary & Expert-Curated Trade Recommendations - Newser
Neurocrine Biosciences Inc. stock trendline breakdownQuarterly Market Summary & Risk Managed Investment Strategies - Newser
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.84%
자본화:
|
볼륨(24시간):